Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034065 (pulmonary embolism)
 14,979 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We report herein on a case of renal cell carcinoma with retrohepatic inferior vena cava tumor thrombus in which intraoperative cardiac arrest from a massive pulmonary embolism was managed successfully with emergency sternotomy and cardiopulmonary bypass, followed by the removal of the primary site and pulmonary artery embolus.
 ...
PMID:Successful recovery from a massive pulmonary artery tumor embolism occurring during surgery for renal cell carcinoma. 1470 16

Renal cell carcinoma with tumor thrombus extension into the inferior vena cava (IVC) remains a difficult operative challenge. Placement of a suprarenal "temporary" IVC filter, with its ease of insertion and removal, makes it the ideal treatment to prevent pulmonary embolism in these difficult cases. We report the first 2 cases of temporary suprarenal IVC filters placed at the time of radical nephrectomy to eliminate the possibility of perioperative pulmonary embolus and avoid the potential long-term sequelae of a permanent suprarenal IVC filter.
 ...
PMID:Renal cell carcinoma invading the inferior vena cava: use of a "temporary" vena cava filter to prevent tumor emboli during nephrectomy. 1497

Metastatic hepatic tumours can be treated with hepatic transcatheter arterial chemoembolization (TACE). Common complications associated with TACE include hepatic insufficiency, fever, and pain. However, pulmonary embolism is rarely documented as a fatal adverse effect. We report a case of pulmonary embolism following TACE in a renal cell carcinoma patient with liver metastases. Total recovery is noted after the effective treatment.
 ...
PMID:Pulmonary embolism after transcatheter arterial chemoembolization. 1627 65

Malignant neoplasms such as renal cell carcinoma may invade the inferior vena cava leading to a risk of pulmonary tumour embolization during surgical excision. Although massive pulmonary tumour embolism occurs relatively rarely, it can have catastrophic consequences. We report the case of an acute intraoperative pulmonary tumour embolism during resection of a renal cell carcinoma. The use of transoesophageal echocardiography allowed the immediate diagnosis and appropriate management of the underlying cause of acute haemodynamic instability. The role of transoesophageal echocardiography in the diagnosis of pulmonary embolism is discussed.
 ...
PMID:Value of transoesophageal echocardiography for diagnosis of intraoperative tumour embolization. 1718 1

Venous thromboembolism is a common complication in patients with cancer and an important cause of morbidity and mortality. Idiopathic thrombosis, migratory or recurrent thrombophlebitis may be the first manifestation of an occult malignancy. While deep venous thrombosis and pulmonary embolism are the most common thrombotic conditions in patients with malignant disease, tumor thrombus may be seen in inferior vena cava, mainly in patients with renal cell carcinoma, hepatocellular carcinoma, testicular tumors or adrenal carcinoma. Although pancreatic cancer is one of the cancers that are most strongly associated with thrombotic complications along with cancers of ovary and brain, there has been no report about presence of thrombus in the inferior vena cava in pancreatic cancer. We report a female patient with pancreatic cancer associated with tumor thrombus extending from the inferior vena cava to the right atrium.
 ...
PMID:Inferior vena caval tumor thrombus extending into the right atrium in a patient with pancreatic cancer. 1748 76

The purpose of this study is to assess the impact on clinical decision making of chest computed tomography (CT) in immunocompetent emergency department (ED) patients with chest radiographic (CXR) findings of pneumonia. We retrospectively identified 1,373 patients from our ED who underwent chest CT between 7/05 and 6/06. Report of CXR within 24 h before CT were reviewed to identify patients with findings of pneumonia. The following were the exclusion criteria: recommendation of CT on CXR report and immunocompromised status on chart review. Fifty-one patients met the inclusion criteria: 26 women and 25 men, with a mean age of 60 (range 29-103) years. Age- and sex-matched controls from the ED with CXR findings of pneumonia who did not undergo CT were identified. Charts were reviewed for clinical presentation, management, and follow-up. Patient and control groups were compared using Fisher exact and paired Student's t tests. The patients were sicker than the controls with more signs and symptoms including auscultation abnormalities, 64 (33 of 51) vs 47% (24 of 51), abnormal sputum 32 (16 of 51) vs 0%, hypoxemia 22 (11 of 51) vs 2% (1 of 51), weight loss, 20 (10 of 51) vs 4% (2 of 51), and night sweats, 16 (8 of 51) vs 2% (1 of 51; p < 0.05 each). Clinical management, (based on CT findings in 31% [16 of 51]), was more extensive for patients than controls: antibiotics initiated 82 (41 of 51) vs 47% (24 of 51), antibiotics changed 29 (15 of 31) vs 0%, procedures performed 24 (12 of 51) vs 0%, and mean length of stay was 8 days vs less than 1 (p < 0.05, each). Sixteen percent (8 of 51) of the patients had alternative/additional diagnosis based on CT: pulmonary embolism, lung cancer, hypersensitivity pneumonitis, multiple myeloma, renal cell carcinoma, small bowel obstruction, lung nodule, and endobronchial mass (n = 1, each). Eight percent (4 of 51) of the patients and no controls were diagnosed with tuberculosis (p = 0.06). Immunocompetent ED patients with CXR findings of pneumonia who underwent chest CT were sicker than those who were not imaged with CT. Chest CT was often useful in guiding therapy or providing an alternative diagnosis.
 ...
PMID:Impact of chest CT on the clinical management of immunocompetent emergency department patients with chest radiographic findings of pneumonia. 1770 Dec 35

(1) Sunitinib, a tyrosine kinase inhibitor, is marketed for the treatment of advanced-stage and metastatic renal carcinoma, and for second-line treatment of gastrointestinal stromal tumours. Sorafenib arrived on the market almost simultaneously for second-line treatment of kidney cancer. (2) In second-line treatment of kidney cancer, two non comparative trials showed an unusually high rate of at least partial tumour regression with sunitinib (25%, compared to only 2% with sorafenib). Head-to-head trials of the two drugs are lacking. Although indirect comparisons are notoriously unreliable, sunitinib appears to provide longer progression-free survival than sorafenib (about 9 months versus 5.5 months), although overall survival times are similar. (3) Preliminary results of a trial comparing sunitinib with interferon alfa as first-line treatments in 750 patients with kidney cancer show a 6-month event-free survival advantage in the sunitinib arm. The precise overall survival time has not yet been calculated. (4) In 312 patients with gastrointestinal stromal tumours in whom imatinib has failed, a double-blind placebo-controlled trial showed that sunitinib prolonged overall survival time, but potential biases undermine these results. (5) The adverse effect profile of sunitinib appears to be similar to those of imatinib and sorafenib, apart from more thyroid disorders. The principal adverse effects are cutaneous, gastrointestinal, cardiovascular and haematological disorders. Arterial hypertension, sometimes severe, occurred in 16% of patients treated with sunitinib. Other serious adverse events included tumour haemorrhage and pulmonary embolism. A risk of cardiac toxicity leading to heart failure cannot currently be ruled out. (6) Sunitinib is metabolised by cytochrome P450 isoenzyme CYP 3A4, increasing the likelihood of drug interactions. (7) These results support the use of sunitinib as second-line therapy for patients with gastrointestinal stromal tumours. Additional clinical evaluation is needed, however. In first-line treatment of kidney cancer, it is preferable to wait for detailed results of the ongoing trial, especially effects on survival time, before judging the possible advantages and disadvantages of sunitinib compared to interferon alfa. In second-line treatment, sorafenib is better-assessed than sunitinib and should therefore be preferred, pending a direct comparison of the two drugs.
 ...
PMID:Sunitinib: new drug. For some gastrointestinal stromal tumours. 1772 33

A 67-year-old man presented with lower-extremity edema and shortness on breath. Cardiac tumor consecutive from the arteria renalis level was admitted by computed tomography (CT) and magnetic resonance imaging (MRI). It flows to the right ventricle at the diastolic phase. The emergency surgery was enforced for the prevention of pulmonary embolism and haemodynamic sustain. The atrial tumor was resected under cardiopulmonary bypass. However, it was difficult to resect completely tumor in the inferior vena cava (IVC), because of infiltration to the wall of IVC. The pathological findings was clear cell carcinoma, so-called renal cell carcinoma. Interferon (IFN) therapy was continued after the operation.
 ...
PMID:[Right atrial tumor that flows to the right ventricule; report of a case]. 1853 2

Radical nephrectomy with inferior vena cava (IVC) thrombectomy remains the most effective therapeutic option in patients with renal cell carcinoma and IVC tumor thrombus. Cephalic extension of the thrombus is closely related to perioperative morbidity. We purposed to design a safe and successful surgical strategy through a review of our surgical experience and treatment results in 35 patients (male:female=28:7, mean age=56 yr [32-77]) who underwent IVC thrombectomy with radical nephrectomy between January 1997 and December 2006. The limit of tumor extension was level I in 10 patients (28.6%), level II in 17 (48.6%), and level III and IV in 4 patients each (11.4%). Liver mobilization with hepatic vascular exclusion was performed in 12 patients and cardiopulmonary bypass in 7. Thirty-two primary closures, 2 patch closures, and 1 graft interposition were performed. One patient underwent simultaneous pulmonary embolectomy because of an operative pulmonary embolism. There was no operative mortality, and the overall survival at 5-yr was 50.8%. Complete thrombus removal without tumor fragmentation under long venotomy on fully exposed involved IVC is recommended for successful result in a bloodless operative field. The applicability of liver mobilization, hepatic vascular exclusion, and cardiopulmonary bypass, can be determined by the level of thrombus.
 ...
PMID:Surgical treatment of inferior vena cava tumor thrombus in patients with renal cell carcinoma. 2005 55

Renal cell carcinoma (RCC) is characterized by a propensity to invade the inferior vena cava (IVC) via the renal vein. It is estimated that such tumor thrombus extension is observed in 4-10% of cases. As the presence of tumor thrombus has not been shown to be a determinant of survival, surgical resection remains the mainstay for treatment. A 57-year-old woman with renal cell carcinoma extending into the right atrium was scheduled for radical nephrectomy and thrombectomy under cardiopulmonary bypass. There was a high possibility of massive bleeding and pulmonary embolism resulting in sudden death during surgical manipulation. Preparing for pulmonary embolism, at the beginning of the operation, a median sternotomy was perfomed to enable us to initiate the CPB immediately. Moreover transesophageal echocardiography (TEE) was perfomed during the operation to detect pulmonary embolism and to recognize the position of the thrombus. In this case, we can detect the cephalad extent of the thrombus during surgical manipulation by continuous TEE monitoring, and notify the information to the surgeons. The use of TEE allowed rapid initiation of CPB before the onset of pulmonary embolism. The monitor showed no signs of pulmonary embolism, and the operation proceeded uneventfully. We recognized the diagnostic power of TEE and its crucial role in a patient having tumor thrombus extending to the IVC.
 ...
PMID:[Anesthetic management of a patient with renal cell carcinoma extending into the right atrium]. 2042 Jan 49


<< Previous 1 2 3 4 5 Next >>